$0.84
-0.04 (-4.30%)
Open$0.86
Previous Close$0.88
Day High$0.88
Day Low$0.83
52W High$1.39
52W Low$0.50
Volume—
Avg Volume68.4K
Market Cap36.41M
P/E Ratio0.70
EPS$1.22
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,216.3% upside
Current
$0.84
$0.84
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.91M | 22.09M | 7.77M |
| Net Income | 60.41M | 86.31M | 1.80M |
| Profit Margin | 434.2% | 412.5% | 23.2% |
| EBITDA | -27,303,137 | -41,177,933 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -37.0% | -37.0% | +3.8% |
| Debt/Equity | — | — | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |